Peptide Receptor Radiotherapy as a Potential Tool of Neoadjuvant Therapy in Patients with Inoperable Neuroendocrine Tumors (NETs)
Introduction: Neoadjuvant treatment is used as pre-surgical therapy in different cancers to decrease tumor size. PRRT can be a useful tool in neoadjuvant treatment of patients with well-differentiated NETs.
Aim(s): To assess using PRRT in primary inoperable NET and show neoadjuvant treatment results in downstaging of the tumor and option of surgery.
Materials and methods: Six patients - five foregut - four PNT, one midgut were included for PRRT every 6-9 weeks. Mean dose - 376 mCi. Tumor mean size was 96.2 mm. Only one patient had metastases to the liver. Cytoreduction chemotherapy was not used.
Conference: 8th Annual ENETSConcerence (2011)
To read the full abstract, please log into your ENETS Member account.